RE: RNS21 Jan 2022 21:57
< Β£70 mn MV
Moat
Proprietary products
Clinical trials results out very soon (if I am not mistaken, in previous presentations, they have mentioned that through their previous extensive trials (and collab with Mt Sinai), they already know that their products are effective. These CTs are a mere formality.
Advisory board is a serious who's who in the kidney transplant world.
Plenty of cash with relatively small cash burn.
Will NOT need FDA approval for commercialisation (taking CLIA path which is much more simple)
Mt Sinai is a shareholder + provide data.
Harwood Capital (with Chris Mills) is a shareholder.
I have invested in other biotech companies. Unlike many others (not dishing them), SMD, LLAI, GENI etc but they do not attract the liquidity that VRCI has.
I am extremely excited to be buying at these prices.
I think this will be a multi-bagger.
PIs who have done their research on this company should know that this is not an AIM mickey mouse outfit.
OK, so they are at nil revenue - hence why market is butchering them at the mo. But for goodness sake, they are only worth Β£68mn.